<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Reported-in-House" dms-id="H72910EDAE9AA40ED89413FB70A07BB06" public-private="public" key="H" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 5526 RH: Seniors’ Access to Critical Medications Act of 2024</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2024-09-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">IB</distribution-code> 
<calendar display="yes">Union Calendar No. 585</calendar> 
<congress display="yes">118th CONGRESS</congress><session display="yes">2d Session</session> 
<legis-num display="yes">H. R. 5526</legis-num> 
<associated-doc role="report" display="yes">[Report No. 118–691, Part I]</associated-doc> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action display="yes"> 
<action-date date="20230918">September 18, 2023</action-date> 
<action-desc><sponsor name-id="H001086">Mrs. Harshbarger</sponsor> (for herself, <cosponsor name-id="W000797">Ms. Wasserman Schultz</cosponsor>, <cosponsor name-id="F000459">Mr. Fleischmann</cosponsor>, <cosponsor name-id="D000230">Mr. Davis of North Carolina</cosponsor>, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, and <cosponsor name-id="B001306">Mr. Balderson</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc> 
</action> 
<action display="yes"> 
<action-date date="20240919">September 19, 2024</action-date> 
<action-desc>Additional sponsors: <cosponsor name-id="J000292">Mr. Johnson of Ohio</cosponsor>, <cosponsor name-id="H001067">Mr. Hudson</cosponsor>, <cosponsor name-id="B001303">Ms. Blunt Rochester</cosponsor>, <cosponsor name-id="L000598">Mr. LaLota</cosponsor>, <cosponsor name-id="R000599">Mr. Ruiz</cosponsor>, <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>, <cosponsor name-id="S001200">Mr. Soto</cosponsor>, <cosponsor name-id="S001185">Ms. Sewell</cosponsor>, <cosponsor name-id="C001068">Mr. Cohen</cosponsor>, <cosponsor name-id="T000487">Ms. Tokuda</cosponsor>, <cosponsor name-id="C001120">Mr. Crenshaw</cosponsor>, <cosponsor name-id="B001257">Mr. Bilirakis</cosponsor>, <cosponsor name-id="J000302">Mr. Joyce of Pennsylvania</cosponsor>, <cosponsor name-id="P000597">Ms. Pingree</cosponsor>, <cosponsor name-id="G000600">Ms. Perez</cosponsor>, <cosponsor name-id="V000133">Mr. Van Drew</cosponsor>, <cosponsor name-id="P000048">Mr. Pfluger</cosponsor>, <cosponsor name-id="P000614">Mr. Pappas</cosponsor>, <cosponsor name-id="F000465">Mr. Ferguson</cosponsor>, <cosponsor name-id="L000585">Mr. LaHood</cosponsor>, <cosponsor name-id="K000382">Ms. Kuster</cosponsor>, <cosponsor name-id="D000628">Mr. Dunn of Florida</cosponsor>, <cosponsor name-id="C001121">Mr. Crow</cosponsor>, <cosponsor name-id="B001275">Mr. Bucshon</cosponsor>, <cosponsor name-id="B001248">Mr. Burgess</cosponsor>, <cosponsor name-id="L000566">Mr. Latta</cosponsor>, <cosponsor name-id="G000592">Mr. Golden of Maine</cosponsor>, <cosponsor name-id="M001205">Mrs. Miller of West Virginia</cosponsor>, <cosponsor name-id="K000391">Mr. Krishnamoorthi</cosponsor>, <cosponsor name-id="R000609">Mr. Rutherford</cosponsor>, <cosponsor name-id="O000019">Mr. Obernolte</cosponsor>, <cosponsor name-id="M000871">Mr. Mann</cosponsor>, <cosponsor name-id="D000616">Mr. DesJarlais</cosponsor>, <cosponsor name-id="B001298">Mr. Bacon</cosponsor>, <cosponsor name-id="N000026">Mr. Nehls</cosponsor>, <cosponsor name-id="B001315">Ms. Budzinski</cosponsor>, <cosponsor name-id="K000392">Mr. Kustoff</cosponsor>, <cosponsor name-id="S001209">Ms. Spanberger</cosponsor>, <cosponsor name-id="G000583">Mr. Gottheimer</cosponsor>, <cosponsor name-id="C001134">Ms. Caraveo</cosponsor>, <cosponsor name-id="G000568">Mr. Griffith</cosponsor>, <cosponsor name-id="S001190">Mr. Schneider</cosponsor>, <cosponsor name-id="J000308">Mr. Jackson of North Carolina</cosponsor>, <cosponsor name-id="C001090">Mr. Cartwright</cosponsor>, <cosponsor name-id="L000600">Mr. Langworthy</cosponsor>, <cosponsor name-id="M001210">Mr. Murphy</cosponsor>, <cosponsor name-id="T000469">Mr. Tonko</cosponsor>, <cosponsor name-id="D000615">Mr. Duncan</cosponsor>, <cosponsor name-id="D000632">Mr. D'Esposito</cosponsor>, <cosponsor name-id="W000828">Mr. Williams of New York</cosponsor>, <cosponsor name-id="R000603">Mr. Rouzer</cosponsor>, <cosponsor name-id="G000590">Mr. Green of Tennessee</cosponsor>, <cosponsor name-id="M000317">Ms. Malliotakis</cosponsor>, <cosponsor name-id="W000814">Mr. Weber of Texas</cosponsor>, <cosponsor name-id="T000165">Mr. Tiffany</cosponsor>, <cosponsor name-id="T000468">Ms. Titus</cosponsor>, <cosponsor name-id="F000468">Mrs. Fletcher</cosponsor>, <cosponsor name-id="R000305">Ms. Ross</cosponsor>, <cosponsor name-id="A000376">Mr. Allred</cosponsor>, <cosponsor name-id="C001051">Mr. Carter of Texas</cosponsor>, <cosponsor name-id="S001159">Ms. Strickland</cosponsor>, <cosponsor name-id="M001224">Mr. Moran</cosponsor>, <cosponsor name-id="E000298">Mr. Estes</cosponsor>, and <cosponsor name-id="P000616">Mr. Phillips</cosponsor></action-desc> 
</action> 
<action display="yes"> 
<action-date date="20240919">September 19, 2024</action-date> 
<action-desc>Reported from the <committee-name added-display-style="italic" committee-id="HIF00" deleted-display-style="strikethrough">Committee on Energy and Commerce</committee-name> with amendments</action-desc> 
<action-instruction>Strike out all after the enacting clause and insert the part printed in italic</action-instruction> 
</action> 
<action display="yes"> 
<action-date date="20240919">September 19, 2024</action-date> 
<action-desc>Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name> discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc> 
<action-instruction>For text of introduced bill, see copy of bill as introduced on September 18, 2023</action-instruction> 
</action> 
<action> 
<action-desc></action-desc> 
</action> 
<legis-type>A BILL</legis-type> 
<official-title display="yes">To amend title XVIII of the Social Security Act to clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for drugs furnished under the Medicare program.<pagebreak/></official-title> 
</form> 
<legis-body display-enacting-clause="yes-display-enacting-clause" changed="added" style="OLC" committee-id="HIF00" reported-display-style="italic" id="H11FE912E8E1F4E19A8B3A8B361D3E1A8"> 
<section id="H46B4B244C313437989912E8E7FD23537" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Seniors’ Access to Critical Medications Act of 2024</short-title></quote>.</text></section> <section id="H6FA804BB780F432BBC0D90765508B1DE"><enum>2.</enum><header>Clarifying the application of the in-office ancillary services exception to the physician self-referral prohibition for covered outpatient drugs furnished under the Medicare program</header> <subsection id="H80D00D2F6ECA4FAA98FEDC5C829DE549"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1877(b)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395nn">42 U.S.C. 1395nn(b)(2)</external-xref>) is amended by adding at the end the following new sentence: <quote>With respect to services described in subsection (h)(6)(J) consisting of covered part D drugs (as defined in section 1860D–2(e)) furnished to an individual during the period beginning on January 1, 2025, and ending on December 31, 2029, such drugs shall be treated as having been furnished in accordance with subparagraph (A)(ii) if such drugs are picked up in a building described in subclause (I) or (II) of such subparagraph by such individual, or a family member or caregiver on behalf of such individual, or delivered to such individual by a mail, delivery, or courier service, but only if, during the 1-year period ending on the date such drugs were so furnished, such individual had a face-to-face encounter with the prescriber of such drugs (not including any such encounter conducted via telehealth), and only if such individual has an ongoing on preexisting relationship with such prescriber.</quote>. </text></subsection> 
<subsection id="HB4B005BB00D1454ABB8F2A7112900C13"><enum>(b)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 3 years after the date of the enactment of this Act, the Secretary of Health and Human Services shall submit to Congress a report that contains—</text> <paragraph id="H340FD01CF1A04EE3BF81253A64751BF5"><enum>(1)</enum><text>the number of individuals who were furnished drugs in a manner that would constitute a violation of section 1877 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395nn">42 U.S.C. 1395nn</external-xref>) but for the amendment made by subsection (a);</text></paragraph> 
<paragraph id="HEFCBE9553CFB41699D457E31AC58124A"><enum>(2)</enum><text>an analysis of the change in expenditures under title XVIII of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395">42 U.S.C. 1395 et seq.</external-xref>) attributable to such amendment;</text></paragraph> <paragraph id="HE5AFF358092141678DEF450FAE92A5A5"><enum>(3)</enum><text>a description of which drugs were furnished in a manner described in paragraph (1); and</text></paragraph> 
<paragraph id="H4613C9680DE3472CB737A5C05180DCDC"><enum>(4)</enum><text>such amendment’s impact on prices for such drugs. </text></paragraph></subsection></section> <section id="HF4F5F1BDA8AB46A6BBD4FB7EFE269DC9" section-type="subsequent-section"><enum>3.</enum><header>Medicare coverage of external infusion pumps and non-self-administrable home infusion drugs</header><text display-inline="no-display-inline">Section 1861(n) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(n)</external-xref>) is amended by adding at the end the following new sentence: </text> 
<quoted-block style="OLC" id="H8F3BEFCA0B214FF79F4E8D84AF883433" display-inline="yes-display-inline"><text>Beginning with the first calendar quarter beginning on or after the date that is one year after the date of the enactment of the <quote><short-title>Seniors’ Access to Critical Medications Act of 2024</short-title></quote>, an external infusion pump and associated home infusion drug (as defined in subsection (iii)(3)(C)) or other associated supplies that do not meet the appropriate for use in the home requirement applied to the definition of durable medical equipment under section 414.202 of title 42, Code of Federal Regulations (or any successor to such regulation) shall be treated as meeting such requirement if each of the following criteria is satisfied:</text> <paragraph id="H1AE3A7714C4B4485BA1E2354310BAE8C"><enum>(1)</enum><text>The prescribing information approved by the Food and Drug Administration for the home infusion drug associated with the pump instructs that the drug should be administered by or under the supervision of a health care professional.</text></paragraph> 
<paragraph id="H197A57986DE84E6F8A6B4E1204A0D3DA"><enum>(2)</enum><text>A qualified home infusion therapy supplier (as defined in subsection (iii)(3)(D)) administers or supervises the administration of the drug or biological in a safe and effective manner in the patient’s home (as defined in subsection (iii)(3)(B)).</text></paragraph> <paragraph id="HBBA1B5FBEC3647F3B979D3BDA647FA24" commented="no"><enum>(3)</enum><text>The prescribing information described in paragraph (1) instructs that the drug should be infused at least 12 times per year—</text> 
<subparagraph id="HB07BB01260334FC088AB509BC7DEC477"><enum>(A)</enum><text>intravenously or subcutaneously; or</text></subparagraph> <subparagraph id="H65DC1D14C8184C91854924C373BEDCED"><enum>(B)</enum><text>at infusion rates that the Secretary determines would require the use of an external infusion pump.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></section> 
<section id="H40572F14A5204C4DB593F60B8CF318E9"><enum>4.</enum><header>Medicare Improvement Fund</header><text display-inline="no-display-inline">Section 1898(b)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395iii">42 U.S.C. 1395iii(b)(1)</external-xref>) is amended by striking <quote>$0</quote> and inserting <quote>$114,000,000</quote>.</text></section> </legis-body><official-title-amendment>Amend the title so as to read: <quote>A bill to amend title XVIII of the Social Security Act to clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for covered outpatient drugs furnished under the Medicare program, and to provide coverage of external infusion pumps and non-self-administrable home infusion drugs under such program.</quote>.</official-title-amendment> <endorsement display="yes"> <action-date date="20240919">September 19, 2024</action-date> <action-desc>Reported from the <committee-name added-display-style="italic" committee-id="HIF00" deleted-display-style="strikethrough">Committee on Energy and Commerce</committee-name> with amendments</action-desc> <action-date date="20240919">September 19, 2024</action-date> <action-desc>Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name> discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc></endorsement> </bill> 

